14th Sep 2016 08:45
LONDON (Alliance News) - Drug discovery & development company ImmuPharma PLC on Wednesday said 11 sites are now active in the US for its Phase III trial of Lupuzor.
Lupuzor is ImmuPharma's programme for the potential breakthrough compound for auto-immune disease lupus.
In addition to the 11 US sites, patients for the trial are being recruited in the Czech Republic, France, Germany, Hungary and Poland, while sites in the UK and Italy are expected to open within the next few weeks.
Last week, ImmuPharma announced that it has been asked to open a site in Mauritius, and on Wednesday said over 10 patients have been pre-screened prior to dosing.
"The key milestone this year remains for the completion of the recruitment of the 200 lupus patients into the trial and we look forward to providing further positive updates on this Lupuzor Phase III study as it progresses throughout this year and 2017," Chairman Tim McCarthy said in a statement.
Shares in ImmuPharma were trading down 1.9% at 38.00 pence on Wednesday morning.
By Karolina Kaminska; [email protected] @KarolinaAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Immupharma